Company Overview of Receptos, Inc.
Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics for immune disorders. Its lead product includes RPC1063, an oral sphingosine 1-phosphate 1 receptor modulator that is in Phase II portion of Phase II/III studies for the treatment of relapsing multiple sclerosis; and is in Phase II studies to treat ulcerative colitis. The company is also developing RPC4046, a monoclonal antibody, which is in Phase II studies for the treatment of eosinophilic esophagitis, an allergic/immune-mediated disorder. In addition, it is involved in a research program for glucagon-like peptide-1 receptor small molecule positiv...
10835 Road to the Cure
San Diego, CA 92121
Founded in 2008
Key Executives for Receptos, Inc.
Chief Executive Officer
Total Annual Compensation: $451.6K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $231.1K
Chief Financial Officer and Principal Accounting Officer
Total Annual Compensation: $254.8K
Chief Medical officer
Total Annual Compensation: $364.3K
Compensation as of Fiscal Year 2013.
Receptos, Inc. Key Developments
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
Dec 22 14
Receptos, Inc. announced that the company has enrolled the first patient in the SUNBEAM Phase 3 trial of RPC1063 in patients with relapsing multiple sclerosis (RMS). The company had previously initiated the Phase 3 portion of the RADIANCE trial in patients with RMS. With both trials now actively enrolling patients, Receptos is on track to complete this Phase 3 clinical development program in 2017. The announcement follows the disclosure in September 2014 of the detailed Phase 2 results of RPC1063 in RMS. In that trial, RPC1063 met the primary endpoint of reduction in MRI brain lesion activity as well as secondary endpoints measuring effects on other MRI parameters. The overall safety profile of RPC1063 was consistent with the results of prior trials and continues to be differentiated on this basis from other oral agents for treatment of RMS. As with the RADIANCE trial, the SUNBEAM trial is a randomized, double-blind study designed to compare 0.5 mg and 1.0 mg of RPC1063 against interferon beta-1a (Avonex®) in 1,200 patients with RMS. The primary objective for the RADIANCE and SUNBEAM trials is to assess whether RPC1063 is superior to Avonex® in reducing the annualized relapse rate in patients after two years of therapy and one year of therapy, respectively. Both Phase 3 trials are being conducted under Special Protocol Assessment (SPA) agreement with the FDA.
Receptos, Inc.(NasdaqGS:RCPT) added to NASDAQ Biotechnology Index
Dec 22 14
Receptos, Inc. will be added to the NASDAQ Biotechnology Index.
Receptos, Inc. Announces Management Changes
Dec 2 14
On December 1, 2014, David Hinkle resigned as Senior Director, Finance & Controller and Chief Accounting Officer of Receptos, Inc. Graham Cooper, the company's Chief Financial Officer, has assumed the role of Principal Accounting Officer, effective immediately.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|